Literature DB >> 8605978

Electrophysiological properties of the hypokalaemic periodic paralysis mutation (R528H) of the skeletal muscle alpha 1s subunit as expressed in mouse L cells.

P Lapie1, C Goudet, J Nargeot, B Fontaine, P Lory.   

Abstract

Hypokalaemic periodic paralysis (HypoPP) is an autosomal dominant muscle disease which has been linked to point mutations in the skeletal muscle L-type calcium channel alpha 1 subunit (alpha 1s). Here, we have introduced one of the point mutations causing HypoPP (R528H) into cDNA of the rabbit alpha 1s. Expression of either the wild-type alpha 1s or the mutant R528H alpha 1s (alpha 1s-R528H) subunits was obtained in mouse Ltk- cells using a selectable expression vector. The alpha 1s-R528H subunit led to the expression of functional L-type Ca2+ channels. Corresponding whole-cell Ba2+ currents exhibit very slow activation and inactivation kinetics, typical for recombinant skeletal Ca2+ channel currents. Voltage-dependent activation and inactivation properties were similar for alpha 1s- and alpha 1s-R528H, as well as their sensitivity to the dihydropyridine agonist Bay K 8644. Differences in alpha 1s- and alpha 1s-R528H-directed channels reside in the Ba2+ current density, which was significantly reduced 3.2 fold in cells expressing alpha 1s-R528H. It was concluded that the R528H mutation af alpha 1s results in minor differences in the electrophysiological properties but significantly reduces the whole-cell Ca2+ channel current in its amplitude.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8605978     DOI: 10.1016/0014-5793(96)00173-1

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  29 in total

1.  The human skeletal muscle Na channel mutation R669H associated with hypokalemic periodic paralysis enhances slow inactivation.

Authors:  A F Struyk; K A Scoggan; D E Bulman; S C Cannon
Journal:  J Neurosci       Date:  2000-12-01       Impact factor: 6.167

Review 2.  Periodic paralysis: understanding channelopathies.

Authors:  Frank Lehmann-Horn; Karin Jurkat-Rott; Reinhardt Rüdel
Journal:  Curr Neurol Neurosci Rep       Date:  2002-01       Impact factor: 5.081

Review 3.  Muscle channelopathies and critical points in functional and genetic studies.

Authors:  Karin Jurkat-Rott; Frank Lehmann-Horn
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

4.  Gating of the HypoPP-1 mutations: I. Mutant-specific effects and cooperativity.

Authors:  Alexey Kuzmenkin; Chao Hang; Elza Kuzmenkina; Karin Jurkat-Rott
Journal:  Pflugers Arch       Date:  2007-02-27       Impact factor: 3.657

Review 5.  Genetic analysis of voltage-dependent calcium channels.

Authors:  C F Fletcher; N G Copeland; N A Jenkins
Journal:  J Bioenerg Biomembr       Date:  1998-08       Impact factor: 2.945

Review 6.  Voltage-sensor mutations in channelopathies of skeletal muscle.

Authors:  Stephen C Cannon
Journal:  J Physiol       Date:  2010-02-15       Impact factor: 5.182

Review 7.  Neuronal P/Q-type calcium channel dysfunction in inherited disorders of the CNS.

Authors:  Sanjeev Rajakulendran; Diego Kaski; Michael G Hanna
Journal:  Nat Rev Neurol       Date:  2012-01-17       Impact factor: 42.937

8.  Elevated resting H+ current in the R1239H type 1 hypokalaemic periodic paralysis mutated Ca2+ channel.

Authors:  Clarisse Fuster; Jimmy Perrot; Christine Berthier; Vincent Jacquemond; Bruno Allard
Journal:  J Physiol       Date:  2017-09-24       Impact factor: 5.182

Review 9.  When muscle Ca2+ channels carry monovalent cations through gating pores: insights into the pathophysiology of type 1 hypokalaemic periodic paralysis.

Authors:  Bruno Allard; Clarisse Fuster
Journal:  J Physiol       Date:  2018-04-15       Impact factor: 5.182

10.  Gating pore currents in DIIS4 mutations of NaV1.4 associated with periodic paralysis: saturation of ion flux and implications for disease pathogenesis.

Authors:  Arie F Struyk; Vladislav S Markin; David Francis; Stephen C Cannon
Journal:  J Gen Physiol       Date:  2008-10       Impact factor: 4.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.